Q3 earnings per share view $0.18 -- Thomson Reuters I/B/E/S * Q3 revenue $153.7 million versus I/B/E/S view $168.5 million * Amag Pharmaceuticals Inc - ‍co has updated 2017 Makena revenue guidance to between $385 million and …
A look at AMAG’s share price movement over the past one year shows that the stock has underperformed the Zacks classified Medical-Biomedical/Genetics industry. Specifically, AMAG’s stock dropped 6.6% during this period, while …
... pay Endoceutics $50 million of total upfront consideration and issue Endoceutics 600,000 unregistered shares of AMAG common stock. Further, AMAG will pay Endoceutics up to $10 million upon delivery of adequate launch quantities of …
One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put AMAG Pharmaceuticals, Inc. AMAG stock into this equation and find out if it …